Roivant Sciences Ltd. (ROIV)
41.85
+0.66
(+1.60%)
USD |
NASDAQ |
Nov 11, 16:00
41.03
-0.82
(-1.96%)
After-Hours: 20:00
Roivant Sciences Enterprise Value : 26.76B for Nov. 11, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 11, 2026 | 26.76B |
| November 10, 2026 | 26.28B |
| November 09, 2026 | 25.91B |
| November 06, 2026 | 24.61B |
| November 05, 2026 | 22.98B |
| November 04, 2026 | 24.14B |
| November 03, 2026 | 22.56B |
| November 02, 2026 | 22.45B |
| October 30, 2026 | 23.19B |
| October 29, 2026 | 23.63B |
| October 28, 2026 | 23.33B |
| October 27, 2026 | 22.92B |
| October 26, 2026 | 22.56B |
| October 23, 2026 | 22.88B |
| October 22, 2026 | 23.58B |
| October 21, 2026 | 23.11B |
| October 20, 2026 | 21.75B |
| October 19, 2026 | 21.59B |
| October 16, 2026 | 20.74B |
| October 15, 2026 | 21.11B |
| October 14, 2026 | 20.80B |
| October 13, 2026 | 20.61B |
| October 12, 2026 | 21.51B |
| October 09, 2026 | 22.12B |
| October 08, 2026 | 21.23B |
| Date | Value |
|---|---|
| October 07, 2026 | 21.62B |
| October 06, 2026 | 22.19B |
| October 05, 2026 | 22.37B |
| October 02, 2026 | 22.32B |
| October 01, 2026 | 22.17B |
| September 30, 2026 | 22.94B |
| September 29, 2026 | 23.33B |
| September 28, 2026 | 23.68B |
| September 25, 2026 | 22.82B |
| September 24, 2026 | 23.06B |
| September 23, 2026 | 23.56B |
| September 22, 2026 | 24.57B |
| September 21, 2026 | 25.13B |
| September 18, 2026 | 25.69B |
| September 17, 2026 | 25.84B |
| September 16, 2026 | 25.55B |
| September 15, 2026 | 25.50B |
| September 14, 2026 | 26.60B |
| September 11, 2026 | 26.45B |
| September 10, 2026 | 26.54B |
| September 09, 2026 | 27.17B |
| September 08, 2026 | 26.93B |
| September 04, 2026 | 22.19B |
| September 03, 2026 | 21.82B |
| September 02, 2026 | 21.65B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bicycle Therapeutics Plc | -268.71M |
| Immunovant, Inc. | 6.937B |
| Adaptimmune Therapeutics Plc | -- |
| Kiniksa Pharmaceuticals International Plc | 6.955B |
| Autolus Therapeutics Plc | 520.23M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -152.97M |
| Revenue (Quarterly) | 35.12M |
| Total Expenses (Quarterly) | 242.50M |
| EPS Diluted (Quarterly) | -0.2869 |
| Gross Profit Margin (Quarterly) | 88.75% |
| Profit Margin (Quarterly) | -435.6% |
| Earnings Yield | -1.34% |
| Normalized Earnings Yield | -3.087 |